Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142).

被引：5
|
作者：
Eads, Jennifer Rachel
Catalano, Paul J.
Fisher, George A.
Klimstra, David S.
Zhang, Zheng
Rubin, Daniel
Iagaru, Andrei
Wong, Terence Z.
O'Dwyer, Peter J.
机构：
[1] Case Western Reserve Univ, Univ Hosp, Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Brown Univ, Providence, RI 02912 USA
[6] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[7] Univ N Carolina, Chapel Hill, NC USA
[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4149
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A randomized phase iib trial of gemcitabine and cisplatin (GC) versus gemcitabine and docetaxel (GD) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC) -: An Galician lung cancer group study
    Rubio, J. Casal
    Estevez, S. Vazquez
    Rivera, F. Vazquez
    Salfago, Mercedes
    Llorca, Cristina
    Ramos, Manuel
    Perez, Eva
    Cervera, Jose M.
    Garcia, Jesus
    Gomez, Jesus Garcia
    Mata, Jesus Garcia
    ANNALS OF ONCOLOGY, 2006, 17 : 224 - 224
  • [32] BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell CarcinomaA Trial of the ECOG-ACRIN Cancer Research Group (E2804)
    Flaherty, Keith T.
    Manola, Judith B.
    Pins, Michael
    McDermott, David F.
    Atkins, Michael B.
    Dutcher, Janice J.
    George, Daniel J.
    Margolin, Kim A.
    DiPaola, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (21) : 2384 - U88
  • [33] A phase II study of gefitinib (G) versus carboplatin and gemcitabine (CG) in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status (PS) 2
    Agarwal, S.
    Hirsh, V.
    Agulnik, J. S.
    Cohen, V.
    Mihalcioiu, C. L.
    Whittom, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
    Neal, Joel W.
    Dahlberg, Suzanne Eleanor
    Wakelee, Heather A.
    Aisner, Seena C.
    Bowden, Michaela
    Carbone, David Paul
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
    Padda, Sukhmani Kaur
    Redman, Mary Weber
    Gerber, David E.
    Stinchcombe, Tom
    Waqar, Saiama Naheed
    Leal, Ticiana
    Minichiello, Katherine
    Reckamp, Karen L.
    Herbst, Roy S.
    Borghaei, Hossein
    Brahmer, Julie R.
    Gray, Jhanelle Elaine
    Kelly, Karen
    Ramalingam, Suresh S.
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
    Boyer, M. J.
    Blackhall, F. H.
    Park, K.
    Barrios, C. H.
    Krzakowski, M. J.
    Taylor, I.
    Liang, J. Q.
    Denis, L. J.
    O'Connell, J. P.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [37] Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321
    Kasai, Takashi
    Mori, Kiyoshi
    Nakamura, Yoichi
    Seki, Nobuhiko
    Ichikawa, Yasuko
    Saito, Haruhiro
    Kondo, Tetsuro
    Nishikawa, Kazuo
    Otsu, Satoshi
    Bessho, Akihiro
    Tanaka, Hiroshi
    Yamaguchi, Hiroyuki
    Kaburagi, Takayuki
    Imai, Hisao
    Mori, Keita
    Ohtake, Junya
    Okamoto, Hiroaki
    CANCER MEDICINE, 2023, 12 (14): : 14988 - 14999
  • [38] Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial
    Karampeazis, A.
    Vamvakas, L.
    Pallis, A. G.
    Christophyllakis, C.
    Kentepozidis, N. K.
    Chandrinos, V.
    Polyzos, A.
    Athanasiadis, A.
    Milaki, G.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] A randomized phase II study comparing a 21-day schedule of Pemetrexed (P) and Gemcitabine (G) versus biweekly P and G in patients with advanced Non-Small Cell Lung Cancer (NSCLC)
    Qi Yingwei
    Molina, Julian R.
    Adjei, Alex A.
    Nelson, Garth
    Nikcevich, Daniel A.
    Rowland, Kendrith M.
    Geeraerts, Louis H.
    Dakhil, Shaker R.
    Obasaju, Coleman K.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S699 - S700
  • [40] FRONT-LINE TREATMENT WITH DOCETAXEL, CISPLATIN AND BEVACIZUMAB FOR PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER: A MULTICENTER PHASE II STUDY OF THE HELLENIC ONCOLOGY RESEARCH GROUP (HORG)
    Kentepozidis, N.
    Agelidou, M.
    Christophylakis, C.
    Kotsakis, A.
    Vardakis, N.
    Stoltidis, D.
    Kontopodis, E.
    Xyrafas, A.
    Agelaki, S.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 436 - 437
12345